Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and…
Ferring’s novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years…
Parsippany, NJ, USA – November 28, 2022 – Ferring Pharmaceuticals appreciates the continued support from New Jersey and Minnesota as…
Investigational RBX2660 showed statistically significant treatment success at reducing CDI recurrence at eight weeks compared to placebo at eight weeks…
A new 24-month subgroup analysis looked at sustained clinical response in participants who received up to two doses of RBX2660…
In collaboration with a multi-disciplinary team of leading experts, FertilityWise offers a convenient, tech-based solution for fertility information. This new…
Subgroup analysis of Phase 3 trial (PUNCH™ CD3) looked at health-related quality of life data in patients treated with RBX2660…
Findings from the analysis underscore Ferring’s commitment to identifying and addressing the needs of healthcare professionals and fertility clinic staff…
Created in partnership with Robyn, a community-driven digital platform, Fertility Outreach evolves the fertility journey by providing a text-based solution…
Parsippany, NJ – October 11, 2022 – Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an…